Journal of Community & Public Health Nursing
Open Access

Thyroid gland; Thyroid disorders; Childcare

Introduction

Congenital hypothyroidism is a condition present at birth, where the thyroid gland fails to produce sufficient thyroid hormones. If left untreated, it can lead to developmental delays and growth issues. Hyperthyroidism occurs when the thyroid gland produces an excessive amount of thyroid hormones. It can cause weight loss, rapid heartbeat, irritability, and other symptoms. Hypothyroidism refers to an underactive thyroid gland that fails to produce an adequate amount of thyroid hormones. It can result in fatigue, weight gain, constipation, and slowed growth in children [1-3].

Methodology

Causes and risk factors

Thyroid disorders in children can have various causes, including:

Genetic factors: Some thyroid disorders have a hereditary component, making children more susceptible if there is a family history.

Autoimmune diseases: Conditions such as Hashimoto's thyroiditis and Graves' disease, where the body's immune system mistakenly attacks the thyroid gland, can affect children.

Certain medications or treatments: Radiation therapy, chemotherapy, or certain medications used in the treatment of other conditions can disrupt thyroid function in children.

Signs and symptoms

Recognizing the signs and symptoms of thyroid disorders in children is crucial for early detection and treatment. Common symptoms include:

Changes in weight and appetite

Fatigue and lethargy

Difficulty concentrating or poor school performance

Growth abnormalities

Mood swings or irritability

Delayed or early puberty

Enlarged thyroid gland (goitre)

Diagnosis and treatment

Diagnosing paediatric thyroid disorders involves a combination of physical examinations, blood tests, and imaging studies. Thyroid function tests measure hormone levels, while imaging techniques such as ultrasound or a thyroid scan help assess the size and structure of the thyroid gland [4 -7].

Treatment options for paediatric thyroid disorders depend on the specific condition diagnosed:

Medication: Most cases of paediatric hypothyroidism can be effectively managed with synthetic thyroid hormone replacement therapy.

Ant thyroid medication: Hyperthyroidism can be treated with medications that help control the excess production of thyroid hormones.

Surgery: In certain cases, surgical removal of the thyroid gland may be necessary, particularly in cases of thyroid nodules or thyroid cancer.

Support and management

Children with thyroid disorders require ongoing monitoring and support. Regular check-ups with a pediatric endocrinologist are essential to adjust medication dosages, track growth and development, and manage any associated complications. Educating the child's caregivers, teachers, and school personnel about the condition can help create a supportive environment for the child's overall well-being [8- 10 ].

Conclusion

Thyroid disorders can affect children of all ages, requiring timely diagnosis and appropriate management. By understanding the different types, causes, symptoms, and available treatments, parents, caregivers, and healthcare professionals can work together to ensure the optimal growth and development of children with thyroid disorders. Early detection, treatment, and ongoing support are key to empowering these young individuals to lead healthy and fulfilling lives.

1. Batty CJ, Tiet P, Bachelder EM, Ainslie KM (2018) Drug Delivery for Cancer Immunotherapy and Vaccines. Pharm. Nanotechnol 6:232-244.

Indexed at , Google Scholar, Crossref

2. Keam SJ (2020) Trastuzumab Deruxtecan: First Approval Drugs. 80:501-508.

Indexed at , Google Scholar, Crossref

3. Lipson EJ, Drake CG (2011) Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. Clin Cancer Res 17:6958-6962.

Indexed at , Google Scholar, Crossref

4. Wei SC, Duffy CR, Allison JP (2018) Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov 8:1069–1086.

Indexed at , Google Scholar, Crossref

5. Markham A, Duggan S (2018) Cemiplimab: First Global Approval Drugs. 78:1841-1846.

Indexed at , Google Scholar, Crossref

6. Zhang F, Qi X, Wang X, Wei D, Wu J, et al. (2017) Structural Basis of the Therapeutic Anti-PD-L1 Antibody Atezolizumab. Oncotarget 8:90215-90224.

Indexed at , Google Scholar, Crossref

7. Lee HT, Lee JY., Lim H, Lee SH., Moon YJ ,et al.(2017) Molecular Mechanism of PD-1/PD-L1 Blockade via Anti-PD-L1 Antibodies Atezolizumab and Durvalumab. Sci Rep 7:5532.

Indexed at , Google Scholar, Crossref

8. Ahmad A (2020). CAR-T Cell Therapy. Int J Mol Sci 21:4303.

Indexed at , Crossref

9. Stein-Merlob AF, Rothberg MV, Holman P, Yang EH (2021) Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Curr Cardiol Rep 23:11.

Indexed at , Google Scholar , Crossref

10. Van den Bulk J, Verdegaal EM, de Miranda NF (2018) Cancer Immunotherapy: Broadening the Scope of Targetable Tumours. Open Biol 8:180037.

Indexed at , Google Scholar , Crossref